EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study

Silvia Novello iD, Dariusz M Kowalski iD, Alexander Luft, Mahmut Gümüş iD, David Vicente, Julien Mazières iD, Jeronimo Rodríguez-Cid iD, Ali Tafreshi, Ying Cheng iD, Ki Hyeong Lee iD, Alexander Golf, Shunichi Sugawara iD und 6 weitere

Journal of Clinical Oncology · 10.04.2023 · 41 (11) · 1999-2006

DOI: 10.1200/jco.22.01990 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.04.2023. Verfasst von Silvia Novello und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University of Turin, Azienda Ospedaliero Universitaria San Luigi, Turin, Italy. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 548-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We report 5-year efficacy and safety outcomes from the phase III KEYNOTE-407 study (ClinicalTrials.gov identifier: NCT02775435 ). Eligible patients with previously untreated, metastatic squamous non–small-cell lung cancer (NSCLC) were randomly assigned 1:1 to pembrolizumab 200 mg or placebo plus carboplatin and paclitaxel/nab-paclitaxel once every 3 weeks for four cycles, followed by pembrolizumab or placebo for up to 35 cycles. Primary end points were overall survival (OS) and progression-free survival (PFS) per RECIST version 1.1 by blinded independent central review (BICR). Five hundred fifty-nine patients were randomly assigned in the intention-to-treat population (pembrolizumab plus chemotherapy, n = 278; placebo plus chemotherapy, n = 281). The median time from random assignment to data cutoff was 56.9 (range, 49.9-66.2) months. OS and PFS were improved with pembrolizumab plus chemotherapy versus placebo plus chemotherapy (hazard ratio [95% CI], 0.71 [0.59 to 0.85] and 0.62 [0.52 to 0.74]), with 5-year OS rates of 18.4% versus 9.7%, respectively. Toxicity was manageable. Among 55 patients who completed 35 cycles of pembrolizumab, the objective response rate was 90.9% and the 3-year OS rate after completion of 35 cycles (approximately 5 years after random assignment) was 69.5%. Pembrolizumab plus chemotherapy maintained an OS and PFS benefit versus placebo plus chemotherapy in previously untreated, metastatic squamous NSCLC and is a standard-of-care first-line treatment option for metastatic squamous NSCLC regardless of programmed death ligand 1 expression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsCarcinoma, Squamous CellHumansAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy Protocols

Substanzen

pembrolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Oncology, University of Turin, Azienda Ospedaliero Universitaria San Luigi, Turin, Italy.
  • Department of Lung Cancer and Thoracic Tumours, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Department of Oncology No. 1 (Thoracic Surgery), Leningrad Regional Clinical Hospital, Saint Petersburg, Russia.
  • Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Turkey.
  • Department of Medical Oncology, Hospital Universitario Virgen Macarena, Sevilla, Spain.
  • Thoracic Oncology, Hôpital Larrey, Centre Hospitalier Universitaire Toulouse, Toulouse, France.

ORCID-Profile: Silvia Novello, Dariusz M Kowalski, Mahmut Gümüş, Julien Mazières, Jeronimo Rodríguez-Cid, Ying Cheng, Ki Hyeong Lee, Shunichi Sugawara, Andrew G Robinson, Balazs Halmos, Luis Paz-Ares

Zitieren

APA

Novello, S., Kowalski, D. M., Luft, A., Gümüş, M., Vicente, D., Mazières, J., Rodríguez-Cid, J., Tafreshi, A., Cheng, Y., Lee, K. H., Golf, A., Sugawara, S., Robinson, A. G., Halmos, B., Jensen, E., Schwarzenberger, P., Pietanza, M. C., & Paz-Ares, L. (2023). Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. Journal of Clinical Oncology, 41(11), 1999-2006. https://doi.org/10.1200/jco.22.01990

Vancouver

Novello S, Kowalski DM, Luft A, Gümüş M, Vicente D, Mazières J, et al. Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. Journal of Clinical Oncology. 2023;41(11):1999-2006. doi:10.1200/jco.22.01990

BibTeX
@article{Novello2023,
  author = {Novello, Silvia and Kowalski, Dariusz M and Luft, Alexander and Gümüş, Mahmut and Vicente, David and Mazières, Julien and Rodríguez-Cid, Jeronimo and Tafreshi, Ali and Cheng, Ying and Lee, Ki Hyeong and Golf, Alexander and Sugawara, Shunichi and Robinson, Andrew G and Halmos, Balazs and Jensen, Erin and Schwarzenberger, Paul and Pietanza, M Catherine and Paz-Ares, Luis},
  title = {Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {11},
  pages = {1999--2006},
  doi = {10.1200/jco.22.01990}
}
Kostenlos starten →